ProQR Therapeutics N.V. Forecast, price target & analysts
ProQR Therapeutics N.V. Target price 2025 - Analyst rating & recommendation
ProQR Therapeutics N.V. Classifications & Recommendation:
ProQR Therapeutics N.V. Price Target
| Target Price | $8.98 |
| Price | $2.34 |
| Potential |
283.68%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target ProQR Therapeutics N.V. 2026 .
The average ProQR Therapeutics N.V. target price is $8.98.
This is
283.68%
register free of charge
$15.27
552.72%
register free of charge
$4.00
70.91%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend ProQR Therapeutics N.V. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the ProQR Therapeutics N.V. stock has an average upside potential 2026 of
283.68%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 7.04 | 16.58 |
| 86.24% | 135.48% | |
| EBITDA Margin | -496.88% | -242.79% |
| 71.81% | 51.14% | |
| Net Margin | -440.89% | -162.77% |
| 78.52% | 63.08% |
7 Analysts have issued a sales forecast ProQR Therapeutics N.V. 2024 . The average ProQR Therapeutics N.V. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an ProQR Therapeutics N.V. EBITDA forecast 2024. The average ProQR Therapeutics N.V. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2 ProQR Therapeutics N.V. Analysts have issued a net profit forecast 2024. The average ProQR Therapeutics N.V. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.38 | -0.33 |
| 60.00% | 13.16% | |
| P/E | negative | |
| EV/Sales | 9.61 |
2 Analysts have issued a ProQR Therapeutics N.V. forecast for earnings per share. The average ProQR Therapeutics N.V. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the ProQR Therapeutics N.V. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
ProQR Therapeutics N.V....
Current ProQR Therapeutics N.V. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Jones Trading | Locked ➜ Locked | Locked | Feb 12 2025 |
| Chardan Capital | Locked ➜ Locked | Locked | Dec 12 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 12 2024 |
| JMP Securities | Locked ➜ Locked | Locked | Dec 12 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 08 2024 |
| Raymond James | Locked ➜ Locked | Locked | Oct 29 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Jones Trading: Locked ➜ Locked
|
Feb 12 2025 |
|
Locked
Chardan Capital: Locked ➜ Locked
|
Dec 12 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 12 2024 |
|
Locked
JMP Securities: Locked ➜ Locked
|
Dec 12 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 08 2024 |
|
Locked
Raymond James: Locked ➜ Locked
|
Oct 29 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
